Sales in comparable stores increased by 5.8 percent in October. Calendar day shifts negatively impacted total comparable sales by 0.3 percentage point, while generic drug introductions in the last 12 months negatively impacted total comparable sales by 0.7 percentage point.
Calendar 2013 sales to date were $60.47 billion , an increase of 4.3 percent from $57.97 billion in 2012.
Fiscal 2014 year-to-date sales for the first two months were $12.29 billion , up 7.0 percent from $11.49 billion in the comparable period in fiscal 2013.
Walgreens opened 14 stores during October, including four relocations, and closed two.
DEERFIELD, Ill. --(BUSINESS WIRE)-- Walgreens (NYSE: WAG) (Nasdaq: WAG) had October sales of $6.37 billion , an increase of 6.1 percent from $6.0 billion for the same month in fiscal 2013.
Total front-end sales increased 3.5 percent compared with the same month in fiscal 2013, while comparable store front-end sales increased 2.3 percent. Customer traffic in comparable stores increased 0.6 percent while basket size increased 1.7 percent.
Prescriptions filled at comparable stores increased by 5.7 percent in October and increased 6.2 percent on a calendar day-shift adjusted basis. This year's October had one additional Thursday and one fewer Monday compared with October 2012 . These calendar shifts negatively impacted prescriptions filled at comparable stores by 0.5 percentage point.
Prescriptions filled at comparable stores also were positively impacted by 1.1 percentage points due to more flu shots versus last year and were negatively impacted by 0.2 percentage point due to lower incidence of flu in this year's October.
October pharmacy sales increased by 7.8 percent, while comparable store pharmacy sales increased 7.9 percent and increased by a calendar day-shift adjusted 8.4 percent. Calendar day shifts negatively impacted pharmacy sales in comparable stores by 0.5 percentage point. Calendar day-shift adjusted comparable store pharmacy sales were negatively impacted by 1.0 percentage point due to generic drug introductions in the last 12 months, and were positively impacted by 0.7 percentage point due to more flu shots versus last year. Pharmacy sales accounted for 65.5 percent of total sales for the month.
Flu shots administered at pharmacies and clinics season to date were more than 4.9 million versus nearly 3.6 million last year.
Walgreen Co.'s (WAG) same-store sales rose 5.8% during October, driven by strong growth in the pharmacy section, while the front of the store also showed improvement.
Analysts polled by Thomson Reuters recently had expected same-store sales growth of 4.6%.
Despite lower gasoline prices, the backdrop of the government shutdown during the month and the debt-ceiling fight had the potential to weigh on consumer spending.
Drug-store retailers have seen a wave of major generic drug introductions put pressure on sales growth. The shift in consumers' drug purchases toward generics has led pharmacy companies to take steps to improve their performance--including a recent agreement by Walgreen and European drug giant Alliance Boots GmbH with drug wholesaler AmerisourceBergen Corp. ( ABC ).
Last month, Walgreen's same-store sales rose 2.3% in the front of the store, below analysts' estimates of 2.8% growth. Same-store customer traffic edged up 0.6% while basket size increased 1.7%.
In the pharmacy section, same-store sales were up 7.9%, above analysts' estimates of 5.6% growth. Same-store prescriptions filled were up 5.7% with a boost from an increase in flu shots. Calendar shifts had a negative impact of half a percentage point in addition to negative impacts from generic drug introductions.
Total October sales rose 6.1% to $6.37 billion .
In 2009, Theraclone and IAVI agreed to collaborate to use Theraclone's novel I-STAR technology for isolating potent monoclonal antibodies to HIV that are broadly neutralizing from the blood of certain HIV-infected individuals who had seemingly developed a protective immune response. Such antibodies have the potential to neutralize many of the types of HIV in circulation worldwide. IAVI retains rights to develop HIV vaccines based on these antibodies, and Theraclone holds and controls the rights to develop therapeutics based on these antibodies.
"This research highlights the power of our I-STAR technology to discover potent antibodies from individuals that have developed a potent and broadly protective immune response in historically difficult-to-treat diseases," said Clifford J. Stocks , Chief Executive Officer of Theraclone. "At this time, we are seeking licensees and strategic partnerships to capitalize on PGT121 and other HIV antibodies which represent a significant opportunity for advancements in the treatment of HIV."
SEATTLE --(BUSINESS WIRE)-- Theraclone Sciences, Inc. , a therapeutic antibody discovery and development company, today announced that collaborators published data in the October 30 th issue of Nature regarding an antibody discovered by Theraclone and the International AIDS Vaccine Initiative (IAVI) with significant potency and breadth against human immunodeficiency virus (HIV). In the study, titled "Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys," researchers demonstrated that a single administration of PGT121 alone and in combination with an additional monoclonal antibody potently reduced levels of simian HIV below detection for weeks after dosing. Importantly, in this study, the virus did not appear to develop resistance to PGT121.
"The discovery of broadly neutralizing antibodies, or bNAbs, such as PGT121, which have the ability to target a large proportion of all major circulating HIV subtypes, has rekindled the pursuit of antibodies in the prevention and treatment of HIV and, according to the investigators in the study, the findings encourage the investigation of monoclonal antibody therapy for HIV-1 in humans," said Kristine Swiderek , Ph.D., CSO of Theraclone Sciences.
As described in an earlier Nature publication in 2011, PGT121, along with a large panel of other anti-HIV bNAbs, was discovered with Theraclone's proprietary I-STAR(TM) technology, which mines the human memory B-cell repertoire of naturally-occurring human antibodies to uncover those with exceptional biological activity. The result is a broadly protective, fully human monoclonal antibody with therapeutic potential to combat HIV infection.
Oh yeah, now I remember. You said I was an idiot for the same reason when I went short the previous time, lol.
Oh well, can't win 'em all. Guess I'll lose everything, we'll see. :)
Yep, but momo stocks move up and down. Nothing is long term. Two weeks ago (posted here) I started a short at 71, shorted more up to 78 (averaged at 76) then covered half at 65 and half at 61 about 10 days ago. I stayed flat while it has run from 61 to today's pop, but feel it's going to turn here (or very soon). We'll see.
FREMONT, Calif. , Nov. 4, 2013 /PRNewswire/ -- The Men's Wearhouse (NYSE: MW) today responded to a request by Jos. A. Bank to conduct due diligence related to the unsolicited, highly-conditional and non-binding proposal by Jos. A. Bank to acquire The Men's Wearhouse , Inc. The Jos. A. Bank proposal is subject to financing, due diligence and regulatory approval conditions.
Following receipt of the due diligence request, the Men's Wearhouse Board of Directors met and, in consultation with its outside financial and legal advisors, concluded that it is not in the best interest of the Company's shareholders to provide Jos. A. Bank with access to nonpublic information concerning Men's Wearhouse. In responding to the due diligence request, the Board noted its determination that the highly-conditional Jos. A. Bank $48.00 per share proposal significantly undervalues Men's Wearhouse .
Douglas S. Ewert , President, Chief Executive Officer and a director of Men's Wearhouse said: "Our Board and management team are committed to creating value for our shareholders. We are enthusiastic about Men's Wearhouse's prospects and are confident that our strategic plan will deliver more value to our shareholders than Jos. A. Bank's inadequate, highly conditional proposal. We thank our shareholders for the support we have received."
The Men's Wearhouse Board, in consultation with its financial and legal advisors, previously evaluated and rejected an unsolicited, highly-conditional and non-binding proposal from Jos. A. Bank to acquire Men's Wearhouse for $48.00 per share in cash, subject to substantial debt and equity financing, due diligence and regulatory approval. The Men's Wearhouse Board concluded that the proposal significantly undervalued Men's Wearhouse and its strong prospects for continued growth and value creation, and was not in the best interests of Men's Wearhouse or its shareholders.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will change the date of its third quarter 2013 conference call to Tuesday, November 12, 2013 , at 8:30 a.m. EST .
The live webcast can be accessed by visiting the investor relations section of the Company's website at xxxxxx. The call can be accessed by dialing 877-703-6108 (domestic) or 857-244-7307 (international) five minutes prior to the start time and providing the pass code 41631121. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks.
It's not the shorts. It's the realization that the puny funding they got was miniscule compared to what they need to stay afloat.
As for the $7 area, that's where I said it would fall to. You've at least got that part right. :)
Predicting a huge short squeeze on this meager funding was silly. If I had been around I would have told you so, lol.
Good luck, in any event.
The increase in the value of Men's Wearhouse shares since our proposal became public makes it obvious that the shareholders of Men's Wearhouse strongly support our transaction. In fact, the market believes that this combination creates over $900 million of value (based on the proposed price for Men's Wearhouse shares and yesterday's closing price for Jos. A. Bank shares compared to the closing price of both stocks on the date prior to our proposal). Despite the market premium generated by our proposal, your board has refused to discuss the proposal with us. Under the circumstances, there is no reason for this process to drag on. If your board has not engaged in good faith discussions with us by November 14, 2013 , we will terminate our proposal in order to consider other strategic alternatives which we have been investigating.
I hope you will agree to engage with us in a thoughtful and responsible dialog.
Robert N. Wildrick , Chairman of the Board Jos. A. Bank Clothiers, Inc.
Several days ago, you published an investor update comparing our proposed transaction against your financial and operating plans for Men's Wearhouse as an independent public company. You went to great lengths to disparage Jos. A. Bank, pointing out the relative size of the companies (yes, we are smaller), suggesting our proposal was opportunistic (yes, we agree it is a great opportunity), and suggesting that our financing is not credible (we can't imagine how it could be more credible at this stage of the process given the quality of our partners). We believe that your shareholders would be best served by your providing us with a limited amount of non-public information so that we can advise you whether we can improve our price. You can then responsibly compare your standalone prospects with the value of our revised proposal. Before you foreclose our offer from your investors, we would hope and expect that you would evaluate in an informed manner the alternatives to create shareholder value. While we believe strongly that our $48 per share cash proposal represents superior, immediate value for the shareholders of Men's Wearhouse when compared to the uncertain discounted present value of your long-term plan, we are nevertheless prepared to consider a price increase.
October 31, 2013
Mr. Douglas S. Ewert , Chief Executive Officer The Men's Wearhouse, Inc. 6100 Stevenson Boulevard Freemont, California 94538
On September 18, 2013 , Jos. A. Bank made a confidential, non-binding proposal to acquire all of the outstanding shares of Men's Wearhouse for $48 per share in cash, representing a premium-to-market of over 40% based on the closing price of Men's Wearhouse's shares the day before we made our proposal. On October 9, 2013 , following an unfortunate news leak (which did not originate from us) describing our proposal, we were forced to make our offer public. Your board rejected our proposal saying that it significantly undervalued Men's Wearhouse and since then has made no effort to engage in any discussions with us on behalf of your shareholders. This letter is to inform you that Jos. A. Bank is willing to consider raising our proposed acquisition price if we are given the opportunity to conduct limited due diligence in order to determine that such an increase would be justified.
Our evaluation of Men's Wearhouse was necessarily based solely on publicly available information. We believe that if we were provided with access to a limited amount of non-public information we could promptly determine whether we could increase our proposed acquisition price. We are, of course, prepared to execute a mutually acceptable non-disclosure agreement to provide Men's Wearhouse with the assurance that any information provided will be kept confidential.
This might take a few posts:
HAMPSTEAD, Md. , Oct. 31, 2013 (GLOBE NEWSWIRE) -- Jos. A. Bank Clothiers, Inc. (Nasdaq:JOSB) today sent the following letter to the Chief Executive Officer of The Men's Wearhouse, Inc. (NYSE:MW). It states that Jos. A. Bank is willing to consider raising the acquisition price it proposed to Men's Wearhouse on September 18, 2013 of $48 per share, or a 42% premium to the closing price of Men's Wearhouse common stock on the day prior, if Jos. A. Bank is given the opportunity to conduct limited due diligence in order to determine that such an increase would be justified. Jos. A. Bank notes that it believes its September 18th proposal represents superior, immediate value for the shareholders of Men's Wearhouse when compared to the uncertain discounted present value of the long-term plan issued by Men's Wearhouse earlier this week.
The letter finally states that, to date, despite the proposed premium and the strong, positive reaction to it in the market, the Board of Directors of Men's Wearhouse has refused to discuss the proposal with Jos. A. Bank. If the Men's Wearhouse Board continues this stance and has not engaged in good faith discussions with Jos. A. Bank by Thursday, November 14, 2013 , Jos. A. Bank will terminate its proposal. Full text of the letter can be found below.
So says CNBC. New information from former employees to be included.
Guess we can add "LIAR" to your list of faults, lol.
Only took a second to find the thread - here is what you said:
verioinc • Sep 4, 2013 4:38 PM
Good ill recall this as it gets back to 20. Your over your head.
Forgive me, it was $20, not $25. But I had the gist of it right.
As for me getting lucky, whatever. If that's how you make yourself feel better, so be it. You seem to be wrong much more often than you're right, but whatever floats your boat.
Best of luck in your trading.